$17.050
-0.198 (-1.16%)收盘时
CTNM 资讯
CTNM 事件
Contineum Cash Resources Sufficient Through Mid-2029
Cash, cash equivalents and marketable securities were $236.6 million as of June 30, 2026. Contineum believes its cash resources are sufficient to fund its planned operations through mid-2029. "We continue to expand our footprint for PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF), with more than 55 sites now online in eight countries to enable a steady pace of enrollment," said Carmine Stengone, CEO, Contineum Therapeutics. "In addition, Johnson & Johnson completed enrollment last month for its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in patients with major depressive disorder (MDD)."
Contineum Therapeutics Publishes PIPE-791 Research Findings
Contineum Therapeutics announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, "Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 (LPAR1) Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders," highlights the Company's internally discovered, selective LPAR1 antagonist as a potentially best-in-class approach for the treatment of fibrotic conditions. "This was an incredible effort by our discovery team to enable the exploration of the full potential of LPAR1 as a therapeutic target for a wide range of indications," said Daniel Lorrain, Ph.D., Chief Scientific Officer, Contineum Therapeutics. "PIPE-791's chemical structure facilitates a slow on-off rate for our compound, differentiated pharmacokinetics and sustained, high target coverage. We believe these unique properties will allow us to pursue a potentially best-in-class approach in several inflammatory and fibrotic diseases."
Contineum Cash Resources Sufficient Through Mid-2029
Cash, cash equivalents and marketable securities were $246.3 million as of March 31, 2026. Contineum believes its cash resources are sufficient to fund its planned operations through mid-2029. "We're excited to have recently shared positive topline results from our chronic pain trial," said Carmine Stengone, CEO, Contineum Therapeutics. "We continue to steadily enroll PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF). With a projected cash runway that extends through mid-2029, which is approximately one year past the estimated completion of our IPF trial, we are maintaining a disciplined approach to capital allocation that prioritizes our lead clinical indication, while thoughtfully considering the advancement of other programs."
Contineum Therapeutics Reports Positive Data from PIPE-791 Trial
Contineum Therapeutics reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potentially best-in-class selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor, for the non-opioid treatment of chronic osteoarthritis pain or chronic low back pain. The randomized, double-blind, placebo-controlled, 4-week, crossover trial enrolled 43 patients (23 COAP and 20 CLBP). The trial design incorporated a washout period for patients prior to the first 4-week treatment period (TP1), after which patients crossed over immediately into a second 4-week treatment period (TP2) without an intervening PIPE-791 washout. PIPE-791 was administered orally at 10mg once-daily.
Contineum Cash Resources Sufficient to Fund Operations Through Mid-2029
Cash, cash equivalents and marketable securities were $262.9 million as of December 31, 2025. Contineum believes its cash resources are sufficient to fund its planned operations through mid-2029. During the fourth quarter, the Company completed an upsized public offering that generated net proceeds of $93.0 million from the issuance of approximately 8.1 million shares of Class A common stock at a price of $12.25. "We're off to a strong start in 2026, having recently dosed the first patient in our global Phase 2 idiopathic pulmonary fibrosis (IPF) trial," said Carmine Stengone, CEO, Contineum Therapeutics. "IPF is a devastating disease that profoundly impacts patients and their families. We're urgently advancing PIPE-791 with the goal of developing a transformative therapy that we believe could address the limitations of current treatments. PIPE-791 may potentially offer an improved dosing, efficacy and tolerability profile to enable sustainable management of this unrelenting disease. With a projected cash runway that extends into mid-2029, which is approximately one year past the estimated completion of our IPF trial, we are maintaining a disciplined approach to capital allocation that prioritizes our lead clinical program, while thoughtfully advancing select discovery programs."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。